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Abstract: SH3 domain-binding protein 2 (SH3BP2) is an adaptor protein that is predominantly
expressed in immune cells, and it regulates intracellular signaling. We had previously reported that a
gain-of-function mutation in SH3BP2 exacerbates inflammation and bone loss in murine arthritis
models. Here, we explored the involvement of SH3BP2 in a lupus model. Sh3bp2 gain-of-function
(P416R knock-in; Sh3bp2KI/+) mice and lupus-prone B6.MRL-Faslpr mice were crossed to yield
double-mutant (Sh3bp2KI/+Faslpr/lpr) mice. We monitored survival rates and proteinuria up to 48
weeks of age and assessed renal damage and serum anti-double-stranded DNA antibody levels.
Additionally, we analyzed B and T cell subsets in lymphoid tissues by flow cytometry and determined
the expression of apoptosis-related molecules in lymph nodes. Sh3bp2 gain-of-function mutation
alleviated the poor survival rate, proteinuria, and glomerulosclerosis and significantly reduced
serum anti-dsDNA antibody levels in Sh3bp2KI/+Faslpr/lpr mice. Additionally, B220+CD4−CD8− T cell
population in lymph nodes was decreased in Sh3bp2KI/+Faslpr/lpr mice, which is possibly associated with
the observed increase in cleaved caspase-3 and tumor necrosis factor levels. Sh3bp2 gain-of-function
mutation ameliorated clinical and immunological phenotypes in lupus-prone mice. Our findings
offer better insight into the unique immunopathological roles of SH3BP2 in autoimmune diseases.
Keywords: SH3 domain–binding protein 2; systemic lupus erythematosus; murine lupus model; Fas;
lpr mutation; double-negative T cells; anti-dsDNA antibody; tumor necrosis factor; macrophages;
dendritic cells
1. Introduction
Systemic lupus erythematosus (SLE) is an autoimmune disease that affects multiple organs [1]
and is characterized by the production of autoantibodies, including an anti-nuclear antibody and
an anti-double-stranded DNA (dsDNA) antibody [2,3]. The presence of autoreactive T and B cell
clones accounts for the increased production of the autoantibodies [2,3]; therefore, the presence of
autoreactive lymphocytes and autoreactive antibodies is a prominent feature of SLE. In addition to the
acquired immune system, the innate immune system also contributes to the induction and progression
of SLE [4]. The inflammatory cytokines produced by the innate immune cells activate the adaptive
immune system and promote tissue damage [4].
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The clinical features of SLE are recapitulated in several animal models [5–7], one of which involves
homozygous Murphy Roths large/lymphoproliferation (lpr) mice (MRL.Faslpr mice), which carry a
loss-of-function mutation in the death-receptor Fas/CD95 gene [8]. The loss-of-function mutation in Fas
results in impaired Fas-mediated apoptosis of autoreactive lymphocytes and subsequent accumulation
of these cells [9]. These lupus-prone mice develop massive lymphoproliferation and visceral-organ
damage associated with increased production of autoreactive lymphocytes and autoantibodies, such as
the anti-dsDNA antibody [7]. The lupus model emphasizes the importance of Fas-mediated peripheral
tolerance in SLE pathogenesis [10,11]. In addition to Fas, other pro-apoptotic factors, including tumor
necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and TNF, are reportedly involved
in the peripheral deletion of pathogenic autoreactive lymphocytes [12–14]; however, the detailed
mechanisms have not yet been clarified.
SH3 domain-binding protein 2 (SH3BP2) is an adapter protein expressed primarily in immune cells,
such as macrophages [15,16], B cells [17,18], and T cells [19]. SH3BP2 regulates immune-cell functions by
interacting with various intracellular signaling proteins, including Syk [20,21], phospholipase Cγ [20,22],
Vav [23,24], and Src [25,26]. SH3BP2 mutations are identified as being responsible for the genetic
disorder cherubism (OMIM no. 118400), characterized by jaw-bone destruction [27]. We had previously
generated Sh3bp2 cherubism-specific Pro416Arg (P416R) mutation knock-in (KI) mice; the mutation
being equivalent to the most common human P418R mutation [15,27]. Analyses of Sh3bp2 P416R-KI
mice revealed enhanced TNF production from activated macrophages [15,16,28,29]. Additionally,
Sh3bp2 gain-of-function mutations reportedly enhance the phagocytic capacity of macrophages [21,30].
Previously, we had reported the involvement of SH3BP2 in the pathogenesis of autoimmune arthritis,
with an Sh3bp2 gain-of-function mutation aggravating joint inflammation and destruction in murine
arthritis models [28,31]. However, the pathological roles of SH3BP2 in other immune-mediated diseases
have not yet been elucidated.
In this study, we investigated the involvement of SH3BP2 in SLE pathophysiology, using Sh3bp2
P416R gain-of-function mice and lupus-prone mice carrying the Faslpr mutation. Our results
demonstrated that Sh3bp2 gain-of-function mutation improved the survival rate and renal involvement
in lupus-prone mice via the reduction in anti-dsDNA antibody titer and autoreactive lymphocytes.
2. Materials and Methods
2.1. Mice
Sh3bp2 P416R gain-of-function mutation KI heterozygous (Sh3bp2KI/+) mice were generated by
introducing a Pro-to-Arg mutation into exon 9 of the murine Sh3bp2 gene, as reported previously [15,31].
B6.MRL-Faslpr mice (C57BL/6J background; referred to as Faslpr mice) were obtained from the Jackson
Laboratory (Bar Harbor, ME, USA). All wild-type (WT) and mutant mice were maintained in the
animal facility of Kawasaki Medical School (Okayama, Japan). All mice were housed in groups
(2–5 mice/cage) and maintained at 22 ◦C under a 12 h:12 h light/dark cycle with free access to water
and standard laboratory food (MF diet, Oriental Yeast Co., Tokyo, Japan). All animal experiments
were approved by the Safety Committee for Recombinant DNA Experiments (Nos. 14-33 and 18-23)
and the Institutional Animal Care and Use Committee of Kawasaki Medical School (Nos. 17-042 and
17-131). All experimental procedures were conducted in accordance with the institutional and National
Institutes of Health guidelines for the humane use of animals.
2.2. Animal Study: Analysis of the Double-Mutant Mice
Faslpr mice were crossed with Sh3bp2KI/+ mice (C57BL/6J background) to yield double-mutant
mice, including WT (n = 8), Sh3bp2KI/+ (n = 7), Faslpr/lpr (n = 12), and Sh3bp2KI/+Faslpr/lpr (n = 8), all of
which were monitored until 48 weeks of age. At the end of the observation period, samples of urine,
blood, lymph node, spleen, and kidney were collected and used for subsequent analyses.
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2.3. Western Blot Analysis
Protein expression in the lymph nodes and spleen was determined by western blot, as described
previously [28,32]. For preparation of protein samples, tissues were harvested from 48-week-old
WT, Sh3bp2KI/+, Faslpr/lpr, and Sh3bp2KI/+Faslpr/lpr mice immediately after euthanasia and soaked in the
RIPA lysis buffer (Sigma-Aldrich, St. Louis, MO, USA) containing a protease inhibitor cocktail (P8340,
Sigma-Aldrich), which in turn contains AEBSF, Aprotinin, Bestatin hydrochloride, E-64, Leupeptin
hemisulfate salt, and Pepstatin A, and phosphatase inhibitor cocktails (P5726, P0044, Sigma-Aldrich).
The tissues were minced using homogenizers. After centrifugation (17,000× g for 15 min at 4 ◦C),
supernatants were collected, and protein concentrations were determined using a BCA protein assay
kit (Thermo Fisher Scientific, Waltham, MA, USA). Protein samples were resolved by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes. After blocking
with 5% skim milk in Tris-buffered saline with 0.1% Tween-20, the membranes were incubated with
the indicated primary antibodies, followed by incubation with the appropriate horseradish peroxidase
(HRP)-conjugated species-specific secondary antibodies. Bands were detected using SuperSignal
West Dura or Femto chemiluminescent substrate (Thermo Fisher Scientific) and visualized using an
ImageQuant LAS-4000 (GE Healthcare, Little Chalfont, UK). Actin was used as a loading control to
normalize the amount of protein. The antibodies used in this study were as follows: anti-SH3BP2
(clone 1E9; Abnova, Taipei City, Taiwan), anti-caspase 3 (D3R6Y; Cell Signaling Technology, Danvers,
MA, USA), and anti-Actin (A2066; Sigma-Aldrich).
2.4. Urine Protein Assessment
Spot urine samples were collected every 8 weeks from the age of 8 weeks. Protein levels in urine
were individually evaluated using urine test strips (Albustix; Siemens Healthineers, Tokyo, Japan).
Levels of proteinuria were semiquantitatively graded from 0 to 3 (0: < 30 mg/dL; 1+: 30–99 mg/dL; 2+:
100–299 mg/dL; 3+: > 300 mg/dL).
2.5. Histopathologic Assessment
Tissue samples were fixed in 4% paraformaldehyde for 2 days and then embedded in paraffin.
Kidney sections (2 µm) were stained with periodic acid-Schiff. Glomerulosclerosis was assessed in a
blinded manner, semiquantitatively, using the glomerulosclerosis index (GSI) as follows [33,34]: a score
of 0 was assigned to normal glomeruli, 1 for up to 25% involvement, 2 for up to 50% involvement, 3 for
up to 75% involvement, and 4 for > 75% sclerosis. The GSI was calculated using the following formula:
GSI = [(1 × N1) + (2 × N2) + (3 × N3) + (4 × N4)]/(N0 + N1 + N2 + N3 + N4) (1)
where NX is the number of glomeruli, with each given score, for a given section. At least 15 glomeruli
were randomly selected from each mouse, and the mean score was calculated therefrom.
2.6. Serum Anti-dsDNA Antibody Measurement
Anti-dsDNA antibody levels in serum samples were measured using an enzyme-linked
immunosorbent assay (ELISA) kit (Shibayagi, Gunma, Japan). Diluted sera (1:100) were incubated
on dsDNA-coated ELISA plates for 2 h at 25 ◦C; after washing, the plates were incubated with
HRP-conjugated goat anti-mouse IgG for 2 h at 25 ◦C. Tetramethylbenzidine was used for detection,
and optical density at 450 nm (OD450) was measured using a microplate reader (Varioskan Flash;
Thermo Fisher Scientific). Concentrations of anti-dsDNA antibodies (IgG) were calculated and
expressed as mU/mL.
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2.7. Serum Immunoglobulin Measurement
Concentrations of isotype-specific immunoglobulins in serum were measured with an ELISA kit
SBA Clonotyping System-C57BL/6-AP (Southern Biotech, Birmingham, AL, USA). Each well in the
96-well plate was incubated with goat anti-mouse immunoglobulin (10 µg/mL) as a capture reagent
at 4 ◦C overnight. Wells were blocked with 1% bovine serum albumin (BSA) in phosphate-buffered
saline (PBS) at 4 ◦C overnight. Diluted serum samples were added to the capture antibody-coated
wells and incubated for 1 h at 25 ◦C with gentle shaking. The wells were then incubated with
alkaline-phosphatase-labeled detection antibodies for 1 h at 25 ◦C. After adding p-nitrophenyl
phosphate substrate, optical densities were measured at 405 nm by a microplate reader (Varioskan
Flash), and the relative quantity of isotype-specific immunoglobulins was determined.
2.8. Flow Cytometry
The subsets of immune cells in the bone marrow, spleen, and lymph nodes were analyzed
with a flow cytometer (FACSCanto II; BD Biosciences, Franklin, NJ, USA). To block FcγR, single-cell
suspensions were incubated with the anti-CD16/CD32 antibody (2.4G2; BD Biosciences) on ice for 10 min
before staining with the indicated monoclonal antibodies. The following monoclonal antibodies were
used in this study: anti-IgM (RMM-1), anti-IgD (11-26c.2a), anti-CD19 (6D5), anti-mouse CD45R/B220
(RA3-6B2), anti-CD43 (S11), anti-CD21/CD35 (7E9), anti-CD23 (B3B4), anti-CD4 (RM4-4), anti-CD8a
(53-6.7), and anti-CD25 (PC61, all from BioLegend, San Diego, CA, USA), and anti-CD3ε (eBioscience,
San Diego, CA, USA); all antibodies were conjugated with fluorochrome. Dead cells were excluded by
7-aminoactinomycin D (7-AAD; BioLegend) staining. In most samples, a minimum of 3 × 104 events
was evaluated, with all data analyzed using FlowJo software (version 9.9.5; BD Biosciences).
2.9. In Vivo Immunization and Measurement of Serum Immunoglobulins Levels
To evaluate antibody production against thymus-independent or -dependent antigens,
serum immunoglobulin levels were quantified after immunization of the mice, as previously
described [17,18,35]. For thymus-independent antigen experiments, 8-week-old WT and Sh3bp2KI /+
mice were immunized intraperitoneally with 50 µg of trinitrophenol conjugated to Ficoll (TNP-Ficoll;
Biosearch Technologies, Petaluma, CA, USA) in sterile PBS, and blood samples were collected at 0-, 7-,
and 14-days post-immunization. For thymus-dependent antigen experiments, 8-week-old WT and
Sh3bp2KI /+ mice were immunized intraperitoneally with 100 µg of TNP-keyhole limpet hemocyanin
(KLH; Biosearch Technologies) in sterile PBS, which was pre-incubated in Imject Alum adjuvant
(Thermo Fisher Scientific). Mice were given booster injections with the same dose at day 14, and blood
samples were collected at 0-, 7-, 14-, and 21-days post-immunization. For anti-TNP ELISA, each well
of the 96-well plate was coated with 100 µL of 10 µg/mL TNP-BSA (Biosearch Technologies) in PBS
at 4 ◦C overnight. Plates were then blocked with 1% BSA in PBS at 4 ◦C overnight, and the relative
quantity of TNP-specific antibodies in each serum sample was determined using an isotype-specific
ELISA kit (SBA Clonotyping System-C57BL/6-AP; Southern Biotech).
2.10. Real-Time Quantitative PCR (qPCR) Analysis
The qPCR analysis was performed as described previously [28,32]. Total RNA samples were
extracted from lymph nodes and cultured cells using RNAiso Plus (Takara Bio, Shiga, Japan) and
solubilized in RNase-free water. The cDNA was synthesized using a Prime Script RT reagent kit (Takara
Bio). The qPCR reactions were performed using SYBR® Green PCR master mix (Takara Bio) with
the StepOnePlus system (Thermo Fisher Scientific). Gene-expression levels relative to hypoxanthine
phosphoribosyltransferase were calculated by the ∆∆Ct method and normalized to baseline controls,
as indicated in each experiment. All qPCR reactions yielded products with single-peak dissociation
curves. Primers used in this study are listed in Table 1.
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Table 1. The quantitative PCR (qPCR) primers used in this study.
Target Genes Gene Accession Number Sequence (5′-3′) Amplicon Size (bp)
Fas NM_007987.2 Forward:Reverse:
taaaccagacttctactgcgattct
gggttccatgttcacacga 73
Fasl NM_010177.4 Forward:Reverse:
aaaaagagccgaggagtgtg
attccagagggatggacctt 66
Tnf NM_013693.2 Forward:Reverse:
catcttctcaaaattcgagtgaca
tgggagtagacaaggtacaaccc 175
Tnfr1 NM_011609.4 Forward:Reverse:
ggaaagtatgtccattctaagaacaa
agtcactcaccaagtaggttcctt 76
Tnfr2 NM_011610.3 Forward:Reverse:
gaggcccaagggtttcag
ggcttccgtgggaagaat 64
Trail NM_ 009425.2 Forward:Reverse:
ggctgcaagtctgcattggg
cctgcagctgcttcatctcgt 192
Trailr2 NM_ 020275.4 Forward:Reverse:
ccacaacacggaacctggca
tgtctgtgaggcccaactgc 167
Tweak NM_ 011614.3 Forward:Reverse:
caggatggagcacaagcag
ggctggagctgttgattttg 73
Dr3 NM_ 001291010.1 Forward:Reverse:
ccctggcttatcccagact
agatgccagaggagttccaa 97
Hprt NM_013556.2 Forward:Reverse:
tcctcctcagaccgctttt
cctggttcatcatcgctaatc 90
Fasl, Fas ligand; Tnf, tumor necrosis factor; Tnfr1, TNF receptor type 1; Tnfr2, TNF receptor type 2; Trail, TNF-related
apoptosis-inducing ligand; Trailr2, TRAIL receptor 2; Tweak, TNF-like weak inducer of apoptosis; Dr3, death receptor
3; Hprt, hypoxanthine phosphoribosyltransferase.
2.11. Bone-Marrow-Derived Dendritic Cell (BMDC) Culture
A crude population of DCs was generated in vitro from mouse bone marrow cells, as described
previously [36], with some modifications. Briefly, bone marrow cells were flushed from the tibia and
femur of the mice; the collected cells were plated at a density of 1 × 106/mL and cultured for 9 days
in 5% CO2 at 37 ◦C in RPMI 1640 medium containing 10% heat-inactivated fetal bovine serum (FBS),
10 ng/mL recombinant mouse granulocyte-macrophage colony stimulating factor (GM-CSF; PeproTech,
Rocky Hill, NJ, USA), and 5 ng/mL mouse interleukin (IL)-4 (PeproTech). The yielded cells were used
as crude BMDCs (CD11c+ cells; 70–80%) for subsequent experiments.
2.12. TNF Measurement by ELISA
TNF concentrations in culture supernatants were measured by sandwich ELISA (R&D Systems,
Minneapolis, MN, USA) [28]. Each well of 96-well plate was coated with the goat anti-mouse TNF
antibody as a capture reagent and incubated at 4 ◦C overnight; thereafter, the wells were washed and
blocked with 1% BSA in PBS at 4 ◦C overnight. Samples and standards were added to the wells and
incubated for 2 h at 25 ◦C. After washing, the wells were incubated with a biotinylated goat anti-mouse
TNF antibody as a detection reagent for 2 h at 25 ◦C and then incubated with streptavidin-HRP substrate
solution. OD450 was measured using a microplate reader (Varioskan Flash), and TNF concentration in
each sample was calculated based on a standard curve.
2.13. Bone Marrow-Derived Macrophage (BMM) Culture
Isolation and culture of primary bone marrow cells were performed, as previously
described [28,31,37]. Briefly, bone marrow cells were isolated from the long bones of 10-week-old female
mice and cultured on Petri dishes for 2 h at 37 ◦C under 5% CO2. Non-adherent bone marrow cells were
re-seeded on culture plates at a density of 1 × 106 cells/mL and then incubated for 2 days in α-minimum
essential medium (α-MEM) containing 10% heat-inactivated FBS and 25 ng/mL recombinant mouse
macrophage colony stimulating factor (M-CSF; PeproTech). After the 2-day pre-culture, the yielded
BMMs were stimulated with lipopolysaccharide (LPS) in the presence of M-CSF. RNA samples were
isolated from BMMs at the indicated time points, and subjected to gene-expression analysis.
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2.14. Phagocytosis Assay
2.14.1. Preparation of Apoptotic Cells
Jurkat cells were cultured in RPMI 1640 containing 10% FBS, 50 µM 2-mercaptoethanol,
and 2 mM L-glutamine. Cells were suspended in PBS and irradiated under an ultraviolet lamp
for 20 min (> 80% cells were trypan blue-positive). Apoptotic Jurkat cells were resuspended in
RPMI 1640 medium and incubated overnight, followed by labeling with IncuCyte pHrodo fluorescent
dye, according to manufacturer’s instructions (Essen BioScience, Ann Arbor, MI, USA). The pHrodo
dye being pH sensitive allows actual detection of ingested apoptotic cells based on the increased
fluorescence emission in the acidic environment of phagocyte-derived phagosomes [38].
2.14.2. Measurement of Phagocytic Activity
Non-adherent bone marrow cells were isolated as described above (Section 2.13) and cultured in
α-MEM containing 10% heat-inactivated FBS and 25 ng/mL M-CSF. On day 9, the yielded BMMs were
collected and seeded onto 96-well plates (2 × 104 cells/well). On day 10, pHrodo-labeled apoptotic
Jurkat cells (5 × 104 cells) were added to each well, and BMMs and apoptotic cells were co-incubated
at 37 ◦C under 5% CO2. Fluorescence intensity (excitation/emission wavelength: 560/585 nm) was
measured at 4 h, 24 h, and 48 h of co-culture using a microplate reader (Varioskan Flash). As a negative
control, pHrodo-labeled Jurkat cells were incubated without BMMs for the same period, and values of
the wells with labeled Jurkat cells alone were subtracted as background.
2.15. Statistical Analysis
All data represent the mean ± standard deviation. Statistical analyses were performed using the
two-tailed unpaired Student’s t-test to compare two groups and one-way analysis of variance (Tukey’s
post hoc test) to compare three or more groups. Survival rates and incidences of proteinuria were
analyzed by Fisher’s exact test. GraphPad Prism v7 (GraphPad Software Inc., San Diego, CA, USA)
was used for all statistical analyses, and a P < 0.05 was considered statistically significant.
3. Results
3.1. Sh3bp2 Gain-Of-Function Mutation Improves the Survival Rate of Lupus-Prone Mice
To explore the involvement of SH3BP2 in SLE pathogenesis, we generated a double-mutant
mouse carrying an Sh3bp2 P416R-KI mutation along with the Faslpr mutation. The Sh3bp2 P416R
mutation contributes to gain-of-function by increasing SH3BP2 stability [39,40]. In Sh3bp2 P416R-KI
mice, SH3BP2 protein accumulates in the cytoplasm, with SH3BP2-mediated pathways subsequently
becoming highly activated [28,31]. We used these mutant mice as an Sh3bp2 gain-of-function model.
We first analyzed SH3BP2 protein expression and found it elevated in the lymph nodes and
spleens of the Sh3bp2KI/+ and Sh3bp2KI/+Faslpr/lpr mice, compared to those in WT and Faslpr/lpr mice
(Figure 1a). This indicated that Sh3bp2KI/+ mutation increased SH3BP2 protein expression, regardless
of the Faslpr mutation, and that Faslpr mutation did not affect SH3BP2 levels.
We observed WT, Sh3bp2KI/+, Faslpr/lpr, and Sh3bp2KI/+Faslpr/lpr mice until the age of 48 weeks,
and found that body weights were comparable between Faslpr/lpr and Sh3bp2KI/+Faslpr/lpr mice (Figure 1b),
and that the extent of splenomegaly in Sh3bp2KI/+Faslpr/lpr mice tended to be milder than that in
Faslpr/lpr mice (Figure 1c). The severity of lymphadenopathy was comparable between Faslpr/lpr
and Sh3bp2KI/+Faslpr/lpr mice (data not shown). Interestingly, Sh3bp2KI/+Faslpr/lpr mice exhibited a
significantly improved survival rate as compared to that of Faslpr/lpr mice (41.7% in Faslpr/lpr vs. 75.0%
in Sh3bp2KI/+Faslpr/lpr mice at 48 weeks) (Figure 1d). This data together indicated that the Sh3bp2
gain-of-function mutation ameliorated pathological conditions in the lupus-prone mice. The improved
phenotypes in the lupus model were opposite to the aggravated phenotypes caused by the Sh3bp2
gain-of-function mutation in murine arthritis models, which we had previously reported [28,31].
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Figure 1. Sh3bp2 gain-of-function mutation improves the survival rate of Faslpr lupus-prone mice.
(a) Immunoblot analysis for SH3BP2. Protein samples were collected from lymph nodes and spleens
of WT, Sh3bp2KI/+, Faslpr/lpr, and Sh3bp2KI/+Faslpr/lpr mice. Actin was used as a loading control. (b–d)
WT (n = 8), Sh3bp2KI/+ (n = 7), Faslpr/lpr (n = 12), and Sh3bp2KI/+Faslpr/lpr mice (n = 8) were monitored
until the age of 48 weeks. At the end of the observation period, body weight (b) and spleen weight (c)
were measured. (d) Survival rates of the mice. Values are presented as the mean ± SD. Note: * p < 0.05;
n.s. = not significant. SH3BP2, SH3 domain-binding protein 2; WT, wild-type; KI, knock-in.
3.2. Sh3bp2 Gain-Of-Function Mutation Improves Renal Involvement in Lupus-Prone Mice
To determine how the Sh3bp2 gain-of-function mutation improves the survival rate of the Faslpr
lupus-prone mice, we examined renal involvement, which is a characteristic feature of lupus-prone
mice [7]. Most Faslpr/lpr mice exhibited profound proteinuria (>100 mg/dL; indicated as ≥2+), whereas
the incidence of severe proteinuria was significantly lower in Sh3bp2KI/+Faslpr/lpr mice relative to that in
Faslpr/lpr mice (100% in Faslpr/lpr vs. 50.0% in Sh3bp2KI/+Faslpr/lpr mice at 48 weeks) (Figure 2a). Histologic
analysis of the kidney revealed the development of glomerulosclerotic lesions in Faslpr/lpr mice, with the
lesions being milder in Sh3bp2KI/+Faslpr/lpr mice (Figure 2b and Figure S1), and represented as a decreased
glomerulosclerosis score (Figure 2c). These findings suggested that the Sh3bp2 gain-of-function
mutation attenuated the progression of renal damage, resulting in the improved survival rate in
Sh3bp2KI/+Faslpr/lpr mice.
3.3. Sh3bp2 Gain-Of-Function Mutation Reduces the Production of Serum Anti-dsDNA Antibody
Autoantibody production is a critical process associated with the development of organ damage
in patients with SLE and lupus-prone mice [2,3,6]. To examine how the Sh3bp2 gain-of-function
mutation modulates the immunological phenotypes in Faslpr lupus-prone mice, we determined serum
concentrations of the anti-dsDNA antibody (IgG). Faslpr/lpr mice exhibited elevated levels of serum
anti-dsDNA, whereas the Sh3bp2 gain-of-function mutation significantly suppressed serum anti-dsDNA
levels in lupus-prone mice at 32 and 48 weeks (Figure 3a), indicating that the Sh3bp2 gain-of-function
mutation negatively regulated autoantibody production in concert with the improved survival rate
(Figure 1d). Additionally, we examined the serum levels of immunoglobulin subclasses (IgM, IgG1,
IgG2b, IgG2c, and IgG3). The finding that all of these were elevated in Faslpr/lpr mice reflected the
aberrant activation of antibody-producing cells. Moreover, we found that the Sh3bp2 gain-of-function
mutation reduced the excessive production of immunoglobulins (Figure 3b).
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Figure 2. Sh3bp2 gain-of-function mutation improves renal involvement in Faslpr lupus-prone mice.
(a) Incidence of proteinuria. WT (n = 7), Sh3bp2KI/+ (n = 7), Faslpr/lpr (n = 5), and Sh3bp2KI/+Faslpr/lpr mice
(n = 6) were monitored until the age of 48 weeks, and levels of proteinuria were monitored every 8
weeks and graded as follows: 0, <30 mg/dL; 1+, 30–99 mg/dL; 2+, 100–299 mg/dL; 3+, >300 mg/dL.
Incidence of proteinuria (≥2+) is presented. (b) Images of periodic acid-Schiff (PAS)-stained kidney
sections from 48-week-old mice. Original magnification, 400×. Bar, 10 µm. (c) Renal glomerulosclerosis
score. Severity of glomerulosclerosis was graded from 0 to 4, with 15 to 20 glomeruli graded per mouse.
Values are presented as the mean ± SD. Note: * p < 0.05. SH3BP2, SH3 domain-binding protein 2; WT,
wild-type; KI, knock-in
Figure 3. Sh3bp2 gain-of-function mutation suppresses aberrant anti-dsDNA antibody and
immunoglobulin production in Faslpr lupus-prone mice. (a,b) Serum samples were collected from WT
(n = 7), Sh3bp2KI/+ (n = 7), Faslpr/lpr (n = 5), and Sh3bp2KI/+Faslpr/lpr mice (n = 5) at 16, 32, and 48 weeks
of age. Levels of anti-dsDNA antibody (a) and each immunoglobulin subclass (b) were determined
by ELISA. Values are presented as the mean ± SD. * p < 0.05; n.s. = not significant. Note: dsDNA,
double-stranded DNA; SH3BP2, SH3 domain-binding protein 2; WT, wild-type; KI, knock-in; ELISA,
enzyme-linked immunosorbent assay.
Next, we determined in vivo antibody production against thymus-independent and -dependent
antigens. WT and Sh3bp2KI/+ mice were immunized with a thymus-independent antigen (TNP-Ficoll)
and a thymus-dependent antigen (TNP-KLH), followed by measurement of serum antibody levels.
Cells 2019, 8, 402 9 of 19
Antibody levels were comparable between WT and Sh3bp2KI/+ mice (Figure 4), suggesting that the
Sh3bp2 gain-of-function mutation did not significantly alter the antibody-producing capacities of
B cells.
Figure 4. Antibody production against thymus-independent (TI) and thymus-dependent (TD) antigens.
Antibody production was comparable between WT (n= 6) and Sh3bp2KI/+ (n= 6) mice. (a) For TI antigen
experiments, 8-week-old WT and Sh3bp2KI/+ mice were immunized with TNP-Ficoll. Blood samples
were collected at 0-, 7-, and 14-days post-immunization, and levels of the anti-TNP antibody (IgG3)
in serum (1:100 dilution) were measured by ELISA. (b) For TD antigen experiments, 8-week-old WT
(n = 3) and Sh3bp2KI/+ (n = 5) mice were immunized with TNP-KLH and given a booster injection with
the same dose at day 14. Blood samples were collected at 0-, 7-, 14-, and 21-days post-immunization,
and levels of the anti-TNP antibody (IgG1) in serum (1:1000 dilution) were measured by ELISA. Note:
SH3BP2, SH3 domain-binding protein 2; WT, wild-type; KI, knock-in; TNP, trinitrophenol; KLH,
keyhole limpet hemocyanin; ELISA, enzyme-linked immunosorbent assay
To further analyze the mechanisms associated with reduced in vivo immunoglobulin production
in lupus-prone mice, we determined the differentiation and maturation status of B cells in the bone
marrow and spleen by flow cytometry. In both bone marrow cells and splenic cells, we observed no
significant difference in the patterns of B cell subsets between Faslpr/lpr and Sh3bp2KI/+Faslpr/lpr mice
(Figure 5a–c), hence suggesting that B cell differentiation and maturation processes are not significantly
altered by Sh3bp2 mutation.
Figure 5. B cell differentiation and maturation are unaltered in Sh3bp2KI/+Faslpr/lpr mice. (a–c) B cell
subsets were analyzed in the bone marrow (a) and spleen (b,c) by flow cytometry. Cells were collected
from WT (n = 7), Sh3bp2KI/+ (n = 7), Faslpr/lpr (n = 5), and Sh3bp2KI/+Faslpr/lpr mice (n = 6) at 48 weeks
of age, and the suspended cells were stained with fluorochrome-labeled antibodies against IgM, IgD,
CD43, and B220 for bone marrow cells (a) and IgM, IgD, CD19, CD23, and CD21/35 for splenic cells (b,c).
All cells were initially gated as 7-AAD-negative single cells, followed by being gated as lymphocytes
(a,b) or CD19+ cells (c). Values are presented as the mean ± SD. Note: * p < 0.05; n.s. = not significant.
SH3BP2, SH3 domain-binding protein 2; WT, wild-type; KI, knock-in; 7-AAD, 7-aminoactinomycin D.
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3.4. Aberrant Accumulation of the B220+CD4−CD8− T cell Population is Ameliorated in
Sh3bp2KI/+Faslpr/lpr Mice
Accumulation of B220+CD4−CD8− T cells, referred to as double-negative T (DNT) cells, is a
prominent feature of Faslpr lupus-prone mice [7,41,42]. It is thought to be caused by impaired peripheral
tolerance [11,43].
To determine the effect of SH3BP2 on T cells, we examined T cell subsets in lymph nodes from
lupus-prone mice and found the ratios of CD4+ T cells, CD8+ T cells, and CD4+CD25+ T cells to
be comparable between Faslpr/lpr and Sh3bp2KI/+Faslpr/lpr mice (Figure 6a). However, the number of
DNT cells in the lymph nodes of Faslpr/lpr mice was significantly elevated relative to that in WT
mice. Interestingly, the number of DNT cells in the lymph nodes was significantly decreased in the
Sh3bp2KI/+Faslpr/lpr mice, compared to that in Faslpr/lpr mice (Figure 6a,b). These findings suggested that
the aberrant accumulation of autoreactive lymphocytes in lupus-prone mice was partly relieved by the
Sh3bp2 gain-of-function mutation.
Figure 6. CD3+B220+CD4−CD8− DNT cells are reduced in the lymph nodes of Sh3bp2KI/+Faslpr/lpr
mice. (a,b) Lymph node cells were collected from WT (n = 7), Sh3bp2KI/+ (n = 7), Faslpr/lpr (n = 5),
and Sh3bp2KI/+Faslpr/lpr mice (n = 6) at 48 weeks of age, and T cell subsets were stained with
fluorochrome-labeled antibodies against CD3, CD4, CD8, CD25, and B220. (a) The ratio of T cell
subsets was analyzed by flow cytometry. All cells were gated as 7-AAD-negative single cells, followed
by being gated as lymphocytes. Values are presented as the mean ± SD; * P < 0.05; n.s. = not
significant. (b) Representative flow cytometry plots of DNT cells in the lymph nodes. Flow cytometry
shows a decreased proportion of DNT cells in the lymphocyte fraction of Sh3bp2KI/+Faslpr/lpr cells.
The number in parentheses indicates the percentage of DNT cells in total lymphocytes. Note: DNT,
double-negative T cell; SH3BP2, SH3 domain-binding protein 2; WT, wild-type; KI, knock-in; 7-AAD,
7-aminoactinomycin D.
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3.5. Sh3bp2KI/+Faslpr/lpr Mice Exhibit Increased Activation of Apoptosis-Inducing Cascades in the Lymph Nodes
We hypothesized that DNT cells might have been effectively deleted in Sh3bp2KI/+Faslpr/lpr mice,
although deletion of the DNT cells was largely disrupted due to the Fas mutation. To examine whether
an apoptotic pathway is activated in the lymph nodes of Sh3bp2KI/+Faslpr/lpr mice, we determined
the levels of caspase-3. We found elevated levels of cleaved caspase-3, an active form of caspase-3,
in the lymph nodes of Sh3bp2KI/+Faslpr/lpr mice (Figure 7a), which suggested increased activation of
apoptotic processes in Sh3bp2KI/+Faslpr/lpr mice. Additionally, we examined the expression of other
apoptosis-related genes in the lymph nodes and found reduced Fas mRNA expression in Faslpr/lpr mice,
consistent with a previous report [44]. Moreover, we found that mRNA levels of both Fas and Fas
ligand (FasL) were comparable between Faslpr/lpr and Sh3bp2KI/+Faslpr/lpr mice (Figure 7b), whereas Tnf
and Tnfr1 mRNA levels in the lymph nodes tended to be elevated in Sh3bp2KI/+Faslpr/lpr mice. However,
there was no significant difference in mRNA expression of Tnfr2, Trail, Trailr2, and Dr3 between the
Faslpr/lpr and Sh3bp2KI/+Faslpr/lpr mice (Figure 7b).
Figure 7. Levels of cleaved caspase-3 are elevated in the lymph nodes of Sh3bp2KI/+Faslpr/lpr mice.
(a) Images of immunoblot for procaspase-3 and cleaved caspase-3. Protein samples were collected
from the lymph nodes of WT (n = 4), Sh3bp2KI/+ (n = 4), Faslpr/lpr (n = 4), and Sh3bp2KI/+Faslpr/lpr (n = 4)
mice. Representative images for procaspase-3 and cleaved caspase-3 are presented. Actin was used as
a loading control. (b) qPCR analysis of apoptosis-related genes. RNA samples were collected from
the lymph nodes of WT (n = 7), Sh3bp2KI/+ (n = 7), Faslpr/lpr (n = 5), and Sh3bp2KI/+Faslpr/lpr (n = 6)
mice at 48 weeks of age, and gene-expression levels relative to that of Hprt were determined and
normalized against levels in WT samples. Values are presented as the mean ± SD. Note: SH3BP2,
SH3 domain-binding protein 2; WT, wild-type; KI, knock-in; Fasl, Fas ligand; Tnf, tumor necrosis factor;
Tnfr1, TNF receptor 1; Tnfr2, TNF receptor type 2; Trail, TNF-related apoptosis-inducing ligand; Trailr2,
TRAIL receptor 2; Tweak, TNF-like weak inducer of apoptosis; Dr3, death receptor 3.
Next, we examined TNF expression in DC and macrophage cultures. We found TNF mRNA and
protein levels to be elevated in DCs from mice with Sh3bp2KI/+ mutation (Figure 8a,b), and Tnf mRNA
to be elevated in LPS-stimulated macrophages from Sh3bp2KI/+ and Sh3bp2KI/+Faslpr/lpr mice (Figure 8c).
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Figure 8. TNF is highly expressed in the Sh3bp2 gain-of-function mutant DCs and macrophages. (a,b)
Bone marrow cells were isolated from 14- to 15-week-old WT, Sh3bp2KI/+, Faslpr/lpr, and Sh3bp2KI/+Faslpr/lpr
mice and pre-cultured with GM-CSF (20 ng/mL) and IL-4 (5 ng/mL) for 8 days; resulting BMDCs were
used for the experiments. (a)Tnf mRNA levels relative to that ofHprtwere determined by qPCR. (b) TNF
protein levels in culture supernatants. Culture supernatants were collected at the end of BMDC culture,
and TNF levels were determined by ELISA. (c) Tnf mRNA expression in BMMs. Bone marrow cells were
isolated from 10- to 12-week-old WT, Sh3bp2KI/+, Faslpr/lpr, and Sh3bp2KI/+Faslpr/lpr mice and stimulated
with M-CSF (25 ng/mL) for 2 days, after which the yielded BMMs were treated with LPS (1 ng/mL) in
the presence of M-CSF (25 ng/mL). Tnf mRNA levels relative to that of Hprt were determined by qPCR.
(d) Phagocytic capacity of BMMs. Apoptotic Jurkat cells were labeled with pH-sensitive fluorescent
dye and co-cultured with BMMs, followed by the measurement of fluorescence intensity derived
from the engulfed apoptotic cells. Values are presented as the mean ± SD. Note: * P < 0.05. SH3BP2,
SH3 domain-binding protein 2; WT, wild-type; KI, knock-in; BMDC, bone marrow-derived dendritic
cell; BMM, bone marrow-derived macrophage; GM-CSF, granulocyte-macrophage colony stimulating
factor; M-CSF, macrophage colony stimulating factor; IL-4, interleukin-4; LPS, lipopolysaccharide; Hprt,
hypoxanthine phosphoribosyltransferase.
3.6. Phagocytic Activity Was Unaltered in Sh3bp2KI/+Faslpr/lpr Mice
Disrupted clearance of self-antigens is reportedly attributed to the development of autoantibodies
in SLE [45,46]. Since the Sh3bp2 gain-of-function mutation reportedly enhanced the phagocytic capacity
of macrophages [21,30], we examined macrophage phagocytosis activity. BMMs were isolated from
the indicated mice, and phagocytic capacities of apoptotic cells were determined. Fluorescence-labeled
apoptotic Jurkat cells were co-cultured with BMMs, and fluorescence intensities derived from engulfed
cells were determined. No detectable difference was found in the phagocytic activity of BMMs from
Faslpr/lpr and Sh3bp2KI/+Faslpr/lpr mice (Figure 8d).
4. Discussion
In this study, we examined the involvement of the adaptor protein SH3BP2 in SLE pathophysiology
using Sh3bp2 gain-of-function mice. Our results revealed that excess SH3BP2 protein ameliorated
immunological and pathological phenotypes in Faslpr lupus-prone mice and that the Sh3bp2
gain-of-function mutation prolonged the survival and reduced the renal involvement in these mice.
The improved phenotypes were associated with suppressed production of the anti-dsDNA antibody
and decreased accumulation of DNT cells in the lymph nodes. Notably, we observed elevated levels
of cleaved caspase-3, which plays a central role in apoptosis progression [47] in the lymph nodes of
Sh3bp2KI/+Faslpr/lpr mice.
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Accumulation of autoreactive lymphocytes is a crucial step in SLE initiation [1]. The Fas-FasL
system is a regulatory mechanism involved in attenuating pathogenic autoreactive lymphocytes [10,11].
Faslpr mice, which possess a loss-of-function mutation in Fas, clearly demonstrate the importance
of Fas-mediated peripheral immune tolerance in the pathogenesis of lupus [2,3]. In the present
study, our findings of decreased DNT cells and increased cleaved caspase-3 levels in lymph nodes
of Sh3bp2KI/+Faslpr/lpr mice led us to speculate that the Sh3bp2 gain-of-function mutation at least
partially rescued the impaired deletion of autoreactive lymphocytes in a Fas-independent manner.
In addition to Fas and FasL, other pro-apoptotic factors also contribute to attenuating pathogenic
autoreactive lymphocytes. TRAIL and TNF induce Fas-independent apoptosis [12–14], and we
observed no difference in Trail mRNA levels in lymph nodes between Faslpr/lpr and Sh3bp2KI/+Faslpr/lpr
mice in the present study, whereas Tnf mRNA expression tended to increase in the lymph nodes
of Sh3bp2KI/+Faslpr/lpr mice. Additionally, we revealed increased production of TNF by myeloid
cells from Sh3bp2KI/+Faslpr/lpr mice. These findings suggested that increased TNF expression in
Sh3bp2KI/+Faslpr/lpr myeloid cells might have contributed to the deletion of DNT cells, resulting in
improved lupus-like phenotypes.
TNF negatively regulates lupus induction. In clinical settings, administration of TNF inhibitors
can trigger the development of autoantibodies and even lupus manifestation (i.e., drug-induced
lupus) in patients with rheumatoid arthritis and inflammatory bowel diseases [48,49]. Although the
mechanisms associated with TNF-inhibitor-induced lupus remain uncertain, several mechanisms have
been hypothesized. According to one, TNF inhibitors induce apoptosis in inflammatory cells, followed
by the excessive release of endogenous immunostimulatory molecules, including self-DNA [50]. As per
another, TNF inhibitors promote autoimmunity by elevating susceptibility to infections or deviating
cytokine production from T helper (Th)2 to Th1 cells [51,52]. In addition to clinical evidence, in vivo
murine models demonstrated the protective effect of TNF in lupus development, showing improvement
in survival rate and renal damage after the administration of TNF to lupus-prone NZB/NZW F1
mice [53]. TNFR1 deficiency reportedly accelerates lymphadenopathy and anti-dsDNA antibody
production in Faslpr lupus-prone mice [14]. Moreover, TNF deficiency aggravates immune-complex
deposition in the kidney associated with increased number of plasmacytoid DCs and elevated levels of
type I interferons in a pristane-induced lupus model [54]. These findings in human SLE and murine
lupus models support our hypothesis that increased TNF expression in Sh3bp2 gain-of-function mutant
cells might ameliorate clinical and immunological phenotypes observed in lupus-prone mice. Contrary
to the protective effect of TNF in the development of SLE, some reports show that TNF contributes to
the progression of SLE. Administration of anti-TNF antibody is reported to attenuate lupus phenotypes
in a murine lupus model with Fasl mutation [55] and in an experimental lupus model [56]. Since TNF
has dualistic suppressive and promotive effects on lupus condition [57], timing and duration of TNF
exposure or inhibition seem to be critical.
SH3BP2 plays multiple roles in various immune cells [58]; however, based on our previous
findings [15,28], Sh3bp2 gain-of-function mutation appears to dominantly regulate the functions of
myeloid cells, rather than of lymphocytes. We had previously shown that the Sh3bp2 gain-of-function
mutation aggravates joint inflammation and destruction in a human TNF-transgenic model and a
collagen-induced arthritis model [28,31]. In the latter model, Sh3bp2KI/+ mutation activated macrophages
and osteoclasts, whereas antibody production and T cell activation were not detectably altered.
These findings together suggested that the Sh3bp2KI/+ mutation dominantly affects the functions of
myeloid cells, but not lymphocytes, in this animal model. The myeloid-cell-dominant effects of the
Sh3bp2 gain-of-function mutation agree with the phenotypes observed in homozygous Sh3bp2KI/KI
mice, which spontaneously develop systemic organ inflammation [15]. The spontaneous inflammation
in Sh3bp2KI/KI mice is dominantly mediated by macrophages, since increased CD11b-positive cells
infiltrate into the inflamed lesions [15]. The inflammatory phenotypes of Sh3bp2KI/KI mice are not
rescued by T and B cell defects induced by Rag-1 deficiency [15]. These findings together support our
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hypothesis that macrophage activation and their increased TNF production in Sh3bp2 gain-of-function
mutant cells may ameliorate clinical and immunological phenotypes of the lupus-prone mice.
Interestingly, the cell types affected by SH2BP2 mutation vary depending on gain- or
loss-of-function. As described, the gain-of-function mutation dominantly affects myeloid cells,
whereas loss-of-function mutation affects both lymphocytes and myeloid cells. We had previously
shown that SH3BP2 deficiency dramatically suppresses the production of anti-type II collagen antibody
without affecting T cell response to type II collagen in a collagen-induced arthritis model [37].
Additionally, B cell-dominant effects of SH3BP2 deficiency were reported by two groups, revealing
that SH3BP2 deficiency impairs the optimal responses of B cells, but not of T cells [17,18]. SH3BP2
deficiency appears to impair B cell differentiation, maturation, and proliferation through disrupted
response to the B cell receptor [17]. In addition to its effect on B cells, SH3BP2 deficiency affects the
functions of macrophages by impairing cytokine production, phagocytic activity [21,30], as well as
osteoclast formation [25,37]. In a TNF-transgenic arthritis model, SH3BP2 deficiency decreased joint
destruction via direct suppression of osteoclastogenesis [37]. These findings suggested that SH3BP2
loss-of-function has a broader impact on the cellular functions of various immune cells, whereas Sh3bp2
gain-of-function dominantly affects the function of myeloid cells. This might be due to the different
regulatory mechanisms associated with SH3BP2 expression in each immune cell. Further analyses
using cell-specific mutant mice would be required to clarify these points.
Effects of the Sh3bp2 gain-of-function mutation on disease processes in the lupus model differed
from those observed in previous arthritis models [28,31]. The Sh3bp2 gain-of-function mutation
rescued lupus phenotypes while exacerbating joint inflammation and destruction in murine arthritis
models [28,31]. The differential effects of Sh3bp2 gain-of-function mutation between arthritis and
lupus models might be attributed to the distinct pathological impact of TNF under arthritis and lupus
conditions. TNF is a cytokine critical for the development and progression of arthritis, as shown
by progressive arthritis in murine TNF-transgenic mice [59], and dramatic therapeutic effect of TNF
inhibitors on human rheumatoid arthritis [60]. On the other hand, the contribution of TNF in SLE
progression is limited, as shown by the minor effect of TNF inhibitors on patients with SLE [61].
Conversely, inhibition of TNF raises the risk of inducing lupus-like manifestations [49], as described
here. Therefore, increased TNF expression in Sh3bp2 gain-of-function mutant cells might aggravate
inflammation in arthritic conditions while alleviating immunological and pathological symptoms in
lupus-like conditions.
Impaired phagocytic activity of macrophages reportedly contributes to SLE pathogenesis [62,63].
Suppression of phagocytosis decreases the clearance of self-DNA from apoptotic cells and subsequently
increases levels of self-DNA capable of triggering the production of anti-DNA antibodies [62,63].
SH3BP2 reportedly affects the phagocytic activity of macrophages [21,30]. The phagocytic activity
of U937 cells, a human macrophage cell line, is enhanced following transduction of the human
SH3BP2 P418R mutant, which is equivalent to the murine Sh3bp2 P416R mutation [21]. These findings
prompted our initial hypothesis that elevated phagocytic activity in macrophages harboring the Sh3bp2
gain-of-function mutation might augment the clearance of self-antigens and subsequently suppress
aberrant autoimmune responses. To test this hypothesis, we examined the phagocytosis of apoptotic
cells in BMM culture; however, we did not observe an increased phagocytic activity of Sh3bp2KI/+Faslpr/lpr
macrophages (Figure 8d). Despite this result, we cannot completely exclude the possibility that elevated
phagocytic activity of Sh3bp2KI/+Faslpr/lpr macrophages modifies the clearance of self-DNA leading to
subsequent anti-dsDNA production. The phagocytic activity might vary depending on experimental
settings, as described in previous reports of elevated phagocytic activity of Sh3bp2KI/+ macrophages in
experiments using fluorescence-labeled zymosan and beads [21,30]. Further analyses using various
experimental settings would be required to determine whether SH3BP2-mediated dysregulation of
phagocytic activity affects lupus induction and progression.
Our findings highlighted the pathological roles of macrophages in SLE pathophysiology.
Macrophages regulate the autoimmune system by modulating multiple pathways, not just through
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TNF expression and phagocytic activity. Abnormal expression of monocyte-surface markers, such as
FcγRIII, CD40, CD244, CR4, Siglec-1, and Siglec-4, have been reported in monocytes from patients with
SLE [62,64–66]; therefore, dysregulation of monocyte surface molecules could skew optimal immune
responses, including pathogenic cytokine and chemokine expression [62].
In our study, however, some questions still remain to be answered. First, why splenomegaly
and lymphadenopathy were not significantly retrieved in Sh3bp2KI/+Faslpr/lpr mice is unclear. Detailed
analysis at different time points might reveal improved splenomegaly and lymphadenopathy in
Sh3bp2KI/+Faslpr/lpr mice. Alternatively, Sh3bp2 gain-of-function mutation might promote the growth of
stromal cells in the tissues, considering a recent report that suggested SH3BP2 regulates the growth of
stromal tumor [67]. Second, whether Sh3bp2 gain-of-function mutation could affect the proliferative
and functional characteristics of monocytes and macrophages need to be revealed. Although we
had previously reported that macrophages from Sh3bp2KI/+ mice are hyper-activated in response
to M-CSF and various TLR ligands [15,16], the proliferative and functional characteristics had not
been determined in vivo or in vitro. Determination of these characteristics would facilitate further
understanding of the improved phenotypes of Sh3bp2KI/+Faslpr/lpr mice. Third, whether DNT cells
would be deleted by the TNF expressed by myeloid cells is not understood clearly. Although we
proposed the mechanisms, direct evidence of apoptosis in DNT cells is lacking. To ascertain our
proposed mechanisms, further analyses would be required, e.g., determination of apoptosis in DNT
cells of lymph nodes or in vitro analysis to determine the apoptotic pathway in DNT cells.
Our current study indicated that excess SH3BP2 protein suppressed immunological and clinical
lupus phenotypes. These findings led us to consider the modulation of SH3BP2 expression as a potential
therapeutic approach for SLE, since elevated SH3BP2 protein levels might improve immunological
abnormality and organ involvement in SLE. From this standpoint, tankyrase would likely be a
suitable candidate for drug targeting based on its role as a poly(ADP-ribose) polymerase involved in
regulating SH3BP2 stability [39,40]. Tankyrase ribosylates SH3BP2 and subsequently induces SH3BP2
ubiquitination and degradation [39,40]. We had previously reported that treatment with tankyrase
inhibitors induces SH3BP2 accumulation in macrophages [32]. Therefore, tankyrase inhibition
might potentially ameliorate immunological abnormalities associated with lupus induction and
progression. Since the administration of tankyrase inhibitors induces bone loss [32], the development
of a drug-delivery system would be necessary to advance this therapeutic approach.
5. Conclusions
In conclusion, we demonstrated that the Sh3bp2 gain-of-function mutation ameliorated clinical
and immunological phenotypes in lupus-prone mice and that these improved phenotypes were
associated with decreased autoantibody production and autoreactive lymphocytes, which were likely
induced by activated TNF-producing myeloid cells. Our findings revealed unique immunopathological
consequences associated with the Sh3bp2 gain-of-function mutation in a lupus model and highlighted
the essential roles of myeloid cells in SLE pathogenesis.
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